RE:RE:RE:RE:RE:Conference CallONCY has conducted 2 Phase 2 studies in mBC - IND-213 & Bracelet-1.
12 month OS was reported in June 2023. 2 year OS data will be reported this half and more likely this quarter - taking ONCY into a registrational study for the pelareorep + paclitaxel combination, with an anticipated Accelerated Approval.